A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic LeukemiaPierre Fenaux, Laurent Degos, Philippe Travade et al.|Blood|1999Cited by 745
Gemtuzumab ozogamicin for <i>de novo</i> acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trialJuliette Lambert, Sylvie Castaigné, Cécile Pautas et al.|Haematologica|2018Cited by 349
BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cellsMarie-Magdelaine Coudé, Claude Gardin|Oncotarget|2015Cited by 267
Prognostic impact of<i>DDX41</i>germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO studyNicolas Duployez, Marie Sébert, Laëtitia Largeaud et al.|Blood|2022Cited by 80
Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL): Results of the EWALL-INO StudyPatrice Chevallier, Philippe Rousselot, Thibault Leguay et al.|Blood|2022Cited by 32